Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 4 , Pages 295-301 , December 2008

Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy

  • Hector Alvarez, MD

      Affiliations

    • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • ,
  • Pamela Leal Rojas, MD

      Affiliations

    • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • ,
  • Ken-Tye Yong, PhD

      Affiliations

    • Institute for Lasers, Photonics, and Biophotonics, Department of Chemistry, State University of New York, Buffalo, New York, USA
    • ,
  • Hong Ding, PhD

      Affiliations

    • Institute for Lasers, Photonics, and Biophotonics, Department of Chemistry, State University of New York, Buffalo, New York, USA
    • ,
  • Gaixia Xu, PhD

      Affiliations

    • Institute for Lasers, Photonics, and Biophotonics, Department of Chemistry, State University of New York, Buffalo, New York, USA
    • ,
  • Paras N. Prasad, PhD

      Affiliations

    • Institute for Lasers, Photonics, and Biophotonics, Department of Chemistry, State University of New York, Buffalo, New York, USA
    • ,
  • Jean Wang, MD

      Affiliations

    • Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • ,
  • Marcia Canto, MD

      Affiliations

    • Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • ,
  • James R. Eshleman, MD, PhD

      Affiliations

    • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • ,
  • Elizabeth A. Montgomery, MD

      Affiliations

    • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • ,
  • Anirban Maitra, MBBS

      Affiliations

    • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Corresponding Author InformationCorresponding author. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.

Received 13 January 2008 ,Accepted 25 June 2008.

References 

  1. Paulson TG, Reid BJ. Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell. 2004;6:11–16
  2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–2252
  3. Montgomery E, Goldblum JR, Greenson JK, Haber MM, Lamps LW, Lauwers GY, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol. 2001;32:379–388
  4. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol. 2000;95:1888–1893
  5. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002;11:235–256
  6. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330
  7. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med. 2002;346:836–842
  8. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  9. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93:136–140
  10. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937–3942
  11. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862–3868
  12. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003;63:8614–8622
  13. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000;60:6281–6287
  14. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003;14:4376–4386
  15. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418–1428
  16. McCarthy DM, Maitra A, Argani P, Rader AE, Faigel DO, Van Heek NT, et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol. 2003;11:238–243
  17. Chen Y, Zheng B, Robbins DH, Lewin DN, Mikhitarian K, Graham A, et al. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer. 2007;120:1511–1517
  18. Kachali C, Eltoum I, Horton D, Chhieng DC. Use of mesothelin as a marker for mesothelial cells in cytologic specimens. Semin Diagn Pathol. 2006;23:20–24
  19. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124:838–845
  20. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19:417–428
  21. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol. 2005;29:381–389
  22. Jhala N, Jhala D, Vickers SM, Eltoum I, Batra SK, Manne U, et al. Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol. 2006;126:572–579
  23. Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother. 2000;23:473–479
  24. Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, Bucana CD, et al. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther. 2002;1:595–600
  25. Hung CF, Calizo R, Tsai YC, He L, Wu TC. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine. 2007;25:127–135
  26. Chang CL, Wu TC, Hung CF. Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther. 2007;14:1189–1198
  27. Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004;200:297–306
  28. Corso CD, Stubbs DD, Lee SH, Goggins M, Hruban RH, Hunt WD. Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensor. Cancer Detect Prev. 2006;30:180–187
  29. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest. 2007;132:1239–1246
  30. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol. 2007;106:490–497
  31. Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, Tzeng YL, et al. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res. 2006;26:4721–4728
  32. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006;15:1014–1020
  33. Antonioli DA, Wang HH. Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma. Gastroenterol Clin North Am. 1997;26:495–506
  34. Montgomery E, Mamelak AJ, Gibson M, Maitra A, Sheikh S, Amr SS, et al. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl Immunohistochem Mol Morphol. 2006;14:24–30
  35. Powell EL, Leoni LM, Canto MI, Forastiere AA, Iocobuzio-Donahue CA, Wang JS, et al. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. Am J Surg Pathol. 2005;29:1497–1504
  36. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003;16:902–912
  37. Cao D, Maitra A, Saavedra JA, Klimstra DS, Adsay NV, Hruban RH. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol. 2005;18:752–761
  38. Ito T, Shimada Y, Kan T, David S, Cheng Y, Mori Y, et al. Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. Cancer Res. 2008;68:3214–3224
  39. Yong KT, Qian J, Roy I, Lee HH, Bergey EJ, Tramposch KM, et al. Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells. Nano Lett. 2007;7:761–765
  40. Chang K, Pastan I. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer. 1994;57:90–97
  41. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004;35:357–366
  42. Hansel DE, Dhara S, Huang RC, Ashfaq R, Deasel M, Shimada Y, et al. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol. 2005;29:390–399
  43. Pardridge WM. Gene targeting in vivo with pegylated immunoliposomes. Methods Enzymol. 2003;373:507–528
  44. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65:11631–11638
  45. Qian J, Yong KT, Roy I, Ohulchanskyy TY, Bergey EJ, Lee HH, et al. Imaging pancreatic cancer using surface-functionalized quantum dots. J Phys Chem B. 2007;111:6969–6972
  46. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969–976
  47. Armstrong DK, Laheru D, Ma WW, Cohen SJ, Phillips M, Brahmer J, et al. A phase 1 study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma and ovarian adenocarcinoma. J Clin Oncol. 2007;25:14041

 This work is supported by the D'Amato Foundation. K.T.Y, H.D., G.X., P.N.P., and A.M. are supported by National Cancer Institute grant R01CA119397.

PII: S1549-9634(08)00091-9

doi: 10.1016/j.nano.2008.06.006

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 4 , Pages 295-301 , December 2008

Article Tools

* Image Usage & Resolution